Watchlist Price Alert

CureVac N.V. (CVAC)

NASDAQ: CVAC · Real-Time Price · USD

4.47

-0.16 (-3.46%)

At close: May 30, 2025, 3:59 PM

4.44

-0.78%

After-hours: May 30, 2025, 05:54 PM EDT

-3.46% (1D)

Bid	4.43
Market Cap	1.01B
Revenue (ttm)	535.18M
Net Income (ttm)	162.19M
EPS (ttm)	0.91
PE Ratio (ttm)	4.92
Forward PE	-10.7
Analyst	Buy

Ask	4.8
Volume	815,734
Avg. Volume (20D)	664,700
Open	4.68
Previous Close	4.63
Day's Range	4.45 - 4.68
52-Week Range	2.37 - 5.28
Beta	2.43

About CVAC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CVAC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CVAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

CureVac has released their quartely earnings on May 20, 2025:

Revenue of $939.09K misses estimates by $2.4M, with -92.97% YoY decline.

EPS of -0.24 misses estimates by -0.08, with 27.27% YoY growth.

Why Price Moved

1 week ago

+10.59%

CureVac shares are trading higher following Q1 rep... Unlock content with Pro Subscription

1 month ago

-0.93%

Shares of vaccine stocks are trading lower after CDC advisers begins a review of vaccine guidelines and discussed a more narrow use of COVID-19 booster shots.

News

1 week ago · accessnewswire.com

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...

2 weeks ago · accessnewswire.com

CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE, Pfizer Inc., and others in December 2023 challenging validity of EP 4 023 755 B1 and maintains the patent subject to amendment...

1 month ago · seekingalpha.com

CureVac N.V. (CVAC) Q4 2024 Earnings Call Transcript

CureVac N.V. (NASDAQ:CVAC ) Q4 2024 Earnings Conference Call April 10, 2025 9:00 AM ET Company Participants Sarah Fakih - Vice President, Corporate Communications and Investor Relations Alexander Zehn...

1 month ago · accessnewswire.com

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update

Strategic Milestone Achievement and Increased Financial Discipline Underscore Year of Corporate Transformation Completed enrollment of Part B of Phase 1 glioblastoma study with investigational precisi...

1 month ago · accessnewswire.com

CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025

TÜBINGEN, DE / ACCESS Newswire / April 8, 2025 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biotech company developing a new class of transformative medicines based on messenger ribonucleic acid...

1 month ago · accessnewswire.com

CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer

Significant Regulatory Milestone: U.S. FDA cleared IND application for CVHNLC, CureVac's investigational therapy targeting squamous non-small cell lung cancer Proprietary Epitopes: CVHNLC encodes nove...

2 months ago · benzinga.com

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

CureVac N.V. CVAC on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac's European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.

2 months ago · reuters.com

European Patent Office declares CureVac mRNA patent valid

The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.

2 months ago · accessnewswire.com

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP ...